Please assess the completion status of the following clinical trial:

Trial Title: Effects of Aliskiren, Irbesartan, and the Combination in Hypertensive Patients With Type 2 Diabetes and Diabetic Nephropathy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1/PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Male and/or female subjects between the ages of 30-80 years with a diagnosis of type 2 diabetes (World Health Organization criteria)~* Body mass index (BMI) within the range of 20 and 32.~* Incipient or overt diabetic nephropathy (urinary albumin excretion ≥ 100 but ≤ 2000 mg/day).~* Glomerular filtration rate (GFR) ≥ 40 ml/min documented in the last 4 months prior to randomization~* To be eligible for randomization, patients must fulfill the following criteria:~  1. Patients on ongoing hypertensive therapy must have a blood pressure ≥ 135/85 mmHg but lower than 170/105 mmHg at Visit 2 (Day -1) AND patients must be on stable antihypertensive medications for at least 8 weeks prior to Visit 2 (run-in period).~ 2. Newly diagnosed hypertensive patients must have a blood pressure ≥ 135/85 mmHg but lower than 170/105 mmHg at Visit 2 (Day -1).~* Patients must be on stable hypoglycemic medications for at least 8 weeks prior to Visit 2 (Day -1).~* Patients must be willing and medically able to discontinue all angiotensin-converting enzyme inhibitor (ACEI), angiotensin receptor blocker (ARB), aldosterone receptor antagonist and potassium sparing diuretic medications for the duration of the study.~* Female patients must be postmenopausal, have had a bilateral oophorectomy, or have been surgically sterilized or hysterectomized at least 6 months prior to screening.~* Oral body temperature within the range of 35.0-37.5 °C~* Able to provide written informed consent prior to study participation.~* Able to communicate well with the investigator and comply with the requirements of the study.~Exclusion Criteria:~* Severe hypertension, Grade 3 World Health Organization (WHO) classification (mean sitting diastolic blood pressure \[MSDBP\] ≥ 110 mmHg and/or mean sitting systolic blood pressure \[MSSBP\] ≤ 180 mmHg)~* Acetylsalicylic acid (ASA) treatment \> 1 g/day or regular use of nonsteroidal anti-inflammatory drugs (NSAIDs)~* Kidney disease not caused by diabetes or hypertension~* Serum potassium \< 3.5 or \> 5.1 mEq/L~* GFR \< 40 ml/min/1.73m2 as measured by the Modification of Diet in Renal Disease (MDRD) formula~* Serum albumin \< 2.0 mg/dL~* History of hypertensive encephalopathy or cerebrovascular accident in the last 12 months prior to Visit 1~* Transient ischemic cerebral attack during the 6 months prior to Visit 1~* Current diagnosis of heart failure (New York Heart Association \[NYHA\] Class II-IV)~* History of myocardial infarction, unstable angina pectoris, coronary bypass surgery, or any percutaneous coronary intervention (PCI) during the 6 months prior to Visit 1~* Second or third degree heart block without a pacemaker~* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia~* Clinically significant valvular heart disease~* Type 1 diabetes mellitus~* Uncontrolled type II diabetes mellitus; hemoglobin subtype A1C (HbA1C) \> 11%~* History of malignancy including leukemia and lymphoma (but not basal cell skin carcinoma) within the past five years~* Participation in any clinical investigation within 4 weeks prior to dosing or longer if required by local regulation.~* Donation or loss of 400 mL or more of blood within 8 weeks prior to dosing.~* Significant illness within the two weeks prior to dosing.~* Any surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of study drugs including, but not limited to, any of the following:~  * History of major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection~ * Currently active or previously active inflammatory bowel disease during the 12 months prior to Visit 1~ * Currently active gastritis, duodenal or gastric ulcers, or gastrointestinal/rectal bleeding during the 3 months prior to Visit 1.~ * Any history of pancreatic injury, pancreatitis or evidence of impaired pancreatic function/injury as indicated by abnormal lipase or amylase~ * Evidence of hepatic disease, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portacaval shunt~ * Current treatment with cholestyramine or colestipol resins~* History of immunocompromise, including a positive test result.~* History of a positive hepatitis B surface antigen (HBsAg) or hepatitis C test result.~* History of drug or alcohol abuse within the 12 months prior to dosing.~* Persons directly involved in the execution of this protocol.~* Any condition that, in the opinion of the investigator or the Novartis medical monitor, would jeopardize the evaluation of efficacy or safety~* History of noncompliance to medical regimens or unwillingness to comply with the study protocol~* Known or suspected contraindications to the study medications, including history of allergy to ACE inhibitors and/or to thiazide diuretics or other sulfonamide derived drug~* Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study~* Use of any prescription drug or over-the-counter (OTC) medication which is prohibited by the protocol.~* Patients who previously participated in any aliskiren study.~Other protocol-defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete